Every 10-Q that Oncotelic Therapeutics Inc (OTLC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OTLC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OTLC filings page.
Oncotelic Therapeutics, Inc. reported total assets of $394.8 million at June 30 2026, driven largely by a Level 3 fair value investment in its GMP Bio joint venture of $388.0 million and a Lunai Bioworks equity investment of $1.4 million.
For Q2 2026, the company generated $250,000 of service revenue and an operating loss of $843,565, but posted net income attributable to Oncotelic of $388,147 due mainly to a $1.1 million gain on derecognition of a non‑financial asset and a $300,000 gain on its Lunai investment. For the six months, it recorded a net loss of $1.9 million and operating cash outflow of $434,440, funded by $531,597 of net financing inflows including $500,000 in new convertible debt.
Oncotelic discloses negative working capital of about $16.4 million, total liabilities of $131.3 million (including a $111.6 million deferred tax liability), and substantial convertible and short‑term debt. Management states that recurring losses, limited recent fundraising and liquidity shortfall raise substantial doubt about its ability to continue as a going concern without additional capital.
Oncotelic Therapeutics’ quarter ended March 31, 2026 shows a small cash position and continued losses alongside a very large non‑cash investment asset. Cash was $63,614 with $20,000 in restricted cash, while the company reported a net loss of $2,193,776, wider than a year earlier.
Total assets were $393,955,039, driven mainly by a Level 3 fair value investment in GMP Bio of $388,000,000 and related deferred tax liability of $111,550,000. Stockholders’ equity was $262,211,541 and total liabilities were $131,743,498, but working capital was negative by about $16.3 million.
Management states there is substantial doubt about the company’s ability to continue as a going concern due to recurring losses, limited funding and negative operating cash flow of about $0.3 million for the quarter. To address this, the company has layered convertible debt, including a new ~${398,333} Mast Hill note, and access to a Mast Hill equity purchase agreement for up to $25 million.
Operationally, the JV with Dragon and GMP Bio continues to prepare Phase 2 and 3 trials for OT‑101 and advance five additional nanoparticle cancer therapies. In March 2026, Oncotelic also signed a joint development, manufacturing and licensing agreement with TechForce Robotics to build AI‑enabled, GMP‑compliant robotic systems for pharmaceutical manufacturing.
Oncotelic Therapeutics, Inc. reported no revenue for the three and nine months ended September 30, 2025 and continued to operate at a loss. Net loss attributable to the company was $1.05 million for the quarter, improving from $3.30 million a year earlier, and $1.07 million for the nine‑month period versus $3.92 million in 2024. Operating expenses fell sharply year over year due to the absence of a prior $3.2 million goodwill impairment.
Cash and restricted cash totaled $429,000 at September 30, 2025, while current liabilities were $20.1 million, including $10.3 million of convertible and short‑term debt and $3.5 million of related‑party debt. Management discloses a substantial doubt about the company’s ability to continue as a going concern, citing cumulative losses of about $39.1 million, negative working capital of roughly $18.5 million, and negative operating cash flow. The company is relying on convertible notes, short‑term related‑party loans, and equity purchase agreements with Peak One and Mast Hill, while its 45% stake in JV partner GMP Bio is carried at $22.65 million based on a Level 3 fair value election.